Delivra Health Brands Announces Proposed Share Consolidation
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) has announced plans to implement a 10:1 share consolidation, which will reduce the company's outstanding common shares from 312,617,854 to approximately 31,261,785. The consolidation, approved by the board on January 27, 2025, aims to enhance market appeal and facilitate organic growth.
Shareholders' ownership percentages and voting power will remain largely unchanged, with only minor adjustments for fractional shares. The consolidation will also proportionally adjust the exercise prices and number of shares for existing stock options and warrants. The implementation remains subject to TSX Venture Exchange approval, with the effective date to be announced later.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) ha annunciato piani per implementare una consolidazione delle azioni 10:1, che ridurrà le azioni ordinarie della società da 312.617.854 a circa 31.261.785. La consolidazione, approvata dal consiglio il 27 gennaio 2025, mira ad aumentare l'attrattiva di mercato e a facilitare la crescita organica.
Le percentuali di possesso e il potere di voto degli azionisti rimarranno sostanzialmente invariati, con solo lievi aggiustamenti per le azioni frazionarie. La consolidazione regolerà anche proporzionalmente i prezzi di esercizio e il numero di azioni per le attuali opzioni e warrant. L'attuazione è soggetta all'approvazione della TSX Venture Exchange, con la data di entrata in vigore che sarà annunciata successivamente.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) ha anunciado planes para implementar una consolidación de acciones 10:1, que reducirá las acciones ordinarias de la empresa de 312.617.854 a aproximadamente 31.261.785. La consolidación, aprobada por la junta el 27 de enero de 2025, tiene como objetivo mejorar el atractivo del mercado y facilitar el crecimiento orgánico.
Los porcentajes de propiedad y el poder de voto de los accionistas permanecerán en gran medida sin cambios, con solo ajustes menores para las acciones fraccionarias. La consolidación también ajustará proporcionalmente los precios de ejercicio y el número de acciones para las opciones y warrants existentes. La implementación está sujeta a la aprobación de la TSX Venture Exchange, con la fecha efectiva que se anunciará más adelante.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF)는 10:1 주식 통합을 시행할 계획을 발표했습니다. 이는 회사의 보통주 수를 312,617,854주에서 약 31,261,785주로 줄입니다. 이 통합은 2025년 1월 27일 이사회에서 승인되었으며, 시장 매력을 높이고 유기적 성장을 촉진하는 것을 목표로 합니다.
주주들의 소유 비율과 의결권은 대부분 변화가 없으며, 단지 일부 소액 주주들에 대한 소폭의 조정만 있을 것입니다. 이 통합은 현재의 주식 옵션 및 보증서에 대해 행사 가격과 주식 수를 비례적으로 조정할 것입니다. 시행은 TSX Venture Exchange의 승인을 받아야 하며, 발효 날짜는 추후에 발표될 예정입니다.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) a annoncé des plans pour mettre en œuvre une consolidation des actions 10:1, ce qui réduira les actions ordinaires de l'entreprise de 312.617.854 à environ 31.261.785. La consolidation, approuvée par le conseil d'administration le 27 janvier 2025, vise à renforcer l'attrait du marché et à faciliter la croissance organique.
Les pourcentages de propriété et le pouvoir de vote des actionnaires resteront en grande partie inchangés, avec seulement de légers ajustements pour les actions fractionnaires. La consolidation ajustera également de manière proportionnelle les prix d'exercice et le nombre d'actions pour les options sur actions et les bons de souscription existants. La mise en œuvre reste soumise à l'approbation de la TSX Venture Exchange, la date d'entrée en vigueur étant annoncée ultérieurement.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) hat Pläne zur Umsetzung einer 10:1 Aktienkonsolidierung angekündigt, die die ausstehenden Stammaktien des Unternehmens von 312.617.854 auf ungefähr 31.261.785 reduzieren wird. Die Konsolidierung wurde am 27. Januar 2025 vom Vorstand genehmigt und soll die Marktattraktivität erhöhen und organisches Wachstum erleichtern.
Die Eigentumsanteile und Stimmrechte der Aktionäre bleiben weitgehend unverändert, mit nur geringen Anpassungen für Bruchaktien. Die Konsolidierung wird auch die Ausübungspreise und die Anzahl der Aktien für bestehende Aktienoptionen und Warrants proportional anpassen. Die Umsetzung unterliegt der Genehmigung der TSX Venture Exchange, wobei das Wirksamkeitsdatum später bekannt gegeben wird.
- Share consolidation could improve stock marketability and attract new investors
- No change in shareholders' proportionate ownership and voting rights
- Board approval already secured for the consolidation plan
- Reduction in total outstanding shares from 312.6M to 31.2M may impact trading liquidity
- Implementation still pending TSXV approval, creating execution uncertainty
Vancouver, British Columbia--(Newsfile Corp. - January 27, 2025) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company") is planning to consolidate the Company's issued and outstanding common shares (the "Common Shares") on the basis of one (1) new Common Share for every ten (10) existing Common Shares (the "Consolidation"). Each shareholder's percentage ownership in the Company and proportionate voting power will remain unchanged after the Consolidation, except for minor changes and adjustments resulting from the treatment of any fractional Common Shares.
Management believes the Consolidation will help facilitate ongoing organic growth while providing the Company with increased flexibility for future corporate initiatives. This proposed Consolidation aims to attract new shareholders aligned with the health and wellness sector and improve the marketability of the Common Shares as a compelling investment opportunity.
As a result of the Consolidation, the 312,617,854 Common Shares issued and outstanding prior to the Consolidation will be reduced to approximately 31,261,785 Common Shares. The exercise price of the Company's existing incentive stock options under the Company's
The Consolidation was approved by the board of directors on January 27, 2025, in accordance with the articles of the Company, but remains subject to the approval of the TSX Venture Exchange (the "TSXV"). The effective date of the Consolidation will be determined by the board of directors after all necessary approvals have been obtained. The Company will issue a further news release announcing the effective date of the Consolidation upon receiving TSXV approval. The Company will not be changing its name in conjunction with the Consolidation.
About Delivra Health Brands Inc.
Helping people take control of their health with alternative wellness solutions is what energizes the Delivra Health team! The Delivra Health portfolio features innovative brands like Dream Water® and LivRelief™, which deliver relief from common everyday issues like chronic pain, anxiety, and sleeplessness. Delivra Health products have allowed millions of customers to reclaim their mobility, energy, and in turn, quality of life. The websites of the Company's two subsidiaries are Dream Water® and LivReliefTM. For more information, please visit www.delivrahealthbrands.com.
Cautionary Note Regarding Forward-Looking Statements
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements include, among other things, statements with respect to the timing of the Consolidation and the receipt of TSXV approval.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the cannabis markets where the Company operates; changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; employee relations and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution, and sale of cannabis and cannabis-related products in the markets where the Company operates. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Additional information regarding this and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated March 2, 2021, and under the heading "Risks and Uncertainties" in the Company's management's discussion and analysis for the three months ended September 30, 2024 filed under the Company's profile on SEDAR+ at www.sedarplus.ca.
Investor Relations:
Jack Tasse
Chief Financial Officer
IR@delivrahealth.com
1-877-915-7934
Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238349
FAQ
What is the share consolidation ratio announced by Delivra Health (DHBUF)?
How many shares will DHBUF have after the consolidation?
When will the DHBUF share consolidation take effect?
How will the share consolidation affect DHBUF stockholders' ownership?
Will DHBUF's stock options and warrants be affected by the consolidation?
